Skip to main content
AAN.com
Articles
February 23, 2004

Structural brain abnormalities in multiple sclerosis patients with major depression

February 24, 2004 issue
62 (4) 586-590

Abstract

Objective: To assess the association between major depression and structural brain abnormalities in patients with multiple sclerosis (MS).
Methods: Two groups of patients with clinically definite MS were studied: 21 with Diagnostic and Statistical Manual of Mental Disorders (4th ed.)–defined major depression and 19 without. The groups did not differ on demographic, disease, or cognitive measures. All subjects underwent brain MRI. Tissue segmentation and regional brain masking were applied to the MRI data.
Results: Compared with the euthymic subjects, those with major depression had a greater T2-weighted lesion volume (p = 0.003) and more extensive T1-weighted lesion volume in the left medial inferior prefrontal cortex (p = 0.01) and less gray matter volume (p = 0.01) and more CSF volume in the left anterior temporal region (p = 0.005). A logistic regression analysis identified two independent predictors of depression: left medial inferior prefrontal cortex T2 lesion volume and left anterior temporal CSF volume. These variables accounted for 42% of the depression variance score.
Conclusion: Whereas both lesion burden and atrophy are important in the pathogenesis of depression in MS, psychosocial influences should also be considered.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Arch Neurol. 1990; 47: 98–104.
2.
Feinstein A. The clinical Neuropsychiatry of multiple sclerosis. New York: Cambridge University Press, 1999.
3.
Rao SM, Leo GJ, Haughton VM, St. Aubin–Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989; 39: 161–166.
4.
Honer WG, Hurwitz T, Li DKB, Palmer M, Paty DW. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol. 1987; 44: 187–190.
5.
Feinstein A, Kartsounis L, Miller D, Youl BD, Ron MA. Clinically isolated lesions of the type seen in multiple sclerosis followed up. J Neurol Neurosurg Psychiatry. 1992; 55: 869–876.
6.
Millefiorini E, Padavoni E, Pozzilli C, et al. Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. Acta Neurol Scand. 1992; 86: 354–358.
7.
Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med. 1989; 19: 887–895.
8.
Pujol J, Bello J, Deus J, Marti–Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997; 49: 1105–1110.
9.
Bakshi R, Czarnecki D, Shaikh ZA, Priore R, Janardhan V, Kaliszky Z. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Brain Imag. 2000; 11: 1153–1158.
10.
Fassbender K, Schmidt R, Möβner R, et al. Mood disorders and dysfunction of the hypothalamic–pituitary–adrenal axis in multiple sclerosis. Arch Neurol. 1998; 55: 66–72.
11.
Mohr DC, Cox D, Epstein L, Goldberg A. Brain lesion and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. Psychosom Med. 2002; 64: 130.
12.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983; 13: 227–231.
13.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67: 361–370.
14.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for Axis 1 DSM-IV Disorders—patient edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1994.
15.
McDonald WI, Miller DH, Thompson A. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-β. Ann Neurol. 1994; 36: 14–18.
16.
Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler. 2000; 6: 343–348.
17.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale. Neurology (Cleveland). 1983; 33: 1444–1452.
18.
Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. 1. Frequency, patterns and prediction. Neurology. 1991; 41: 685–691.
19.
Benton AL, Hamsher K de S. Multilingual Aphasia Examination. Iowa City: University of Iowa Press, 1976.
20.
Gronwall DMA. Paced Auditory Serial-Addition Task. A measure of recovery from concussion. Percept Mot Skills. 1977; 44: 367–373.
21.
Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and leaning. Neurology. 1974; 24: 1019–1025.
22.
Barbizet J, Cany E. Clinical and psychometrical study of a patient with memory disturbances. Int J Neurol. 1968; 7: 44–54.
23.
Kovacevic N, Lobaugh NJ, Bronskill MJ, Levine B, Feinstein A, Black SE. A robust method for extraction and automatic segmentation of brain images. Neuroimage. 2002; 17: 1087–1100.
24.
Grabowski TJ, Frank RJ, Szumski NR, Brown CK, Damasio H. Validation of partial tissue segmentation of single-channel magnetic resonance images of the brain. Neuroimage. 2000; 12: 640–656.
25.
Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme Medical, 1988.
26.
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999; 122: 17–26.
27.
Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial study. Brain. 1996; 119: 2009–2019.
28.
Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol. 1990; 28: 57–64.
29.
Mayberg HS, Starkstein SE, Peyser CE, Brandt J, Dannals RF, Folstein SE. Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology. 1992; 42: 1791–1797.
30.
Eastwood MR, Rifat SL, Nobbs H, Ruderman J. Mood disorders following cerebral vascular accident. Br J Psychiatry. 1989; 154: 195–200.
31.
Robinson RG, Kubos KL, Starr LB, Rao K, Price TR. Mood disorders in stroke patients: importance of location of lesion. Brain. 1984; 107: 81–93.
32.
Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet. 2000; 356: 122–126.
33.
Cummings JL. Frontal–subcortical circuits and human behavior. Arch Neurol. 1993; 50: 873–880.
34.
Mayberg HS. Neuroimaging studies of depression in neurological disease. In: Starkstein SE, Robinson RG, eds. Depression in neurological disease. Baltimore: John Hopkins University Press, 1993: 186–216.
35.
Mayberg HS. Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosci. 1994; 6: 428–442.
36.
Feinstein A, Feinstein KJ. Multiple sclerosis and depression: looking beyond diagnosis at symptom expression. J Affect Disord. 2001; 66: 193–198.
37.
Mohr DC, Goodkin DE, Gatto N, Van Der Wende J. Depression, coping, and level of neurological impairment in multiple sclerosis. Mult Scler. 1997; 3: 254–258.
38.
Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping and hope. Mult Scler. 2001; 7: 411–416.
39.
Voss WD, Arnett PA, Higginson CI, Randolph JJ, Campos MD, Dyck CG. Contributing factors to depressed mood in multiple sclerosis. Arch Clin Neuropsychol. 2002; 17: 103–115.
40.
McIvor GP, Riklan M, Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions and perceived social support. J Clin Psychol. 1984; 40: 1028–1033.
41.
Kroencke DC, Denney DR, Lynch SG. Depression during exacerbations in multiple sclerosis: the importance of uncertainty. Mult Scler. 2001; 7: 237–242.
42.
Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime depression in a multiple sclerosis population. Mult Scler. 2000; 6: 115–120.

Information & Authors

Information

Published In

Neurology®
Volume 62Number 4February 24, 2004
Pages: 586-590
PubMed: 14981175

Publication History

Received: April 30, 2003
Accepted: October 19, 2003
Published online: February 23, 2004
Published in print: February 24, 2004

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

A. Feinstein, FRCPC
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.
P. Roy, MS
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.
N. Lobaugh, PhD
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.
K. Feinstein, MA
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.
P. O’Connor, FRCPC
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.
S. Black, FRCPC
From the University of Toronto (Drs. Feinstein, Lobaugh, O’Connor, and Black), Sunnybrook and Women’s College Health Sciences Centre (Drs. Feinstein, Lobaugh, and Black, P. Roy), and St. Michael’s Hospital (Dr. O’Connor, K. Feinstein), Toronto, Ontario, Canada.

Notes

Address correspondence and reprint requests to Dr. A. Feinstein, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Risk Factors for Psychiatric Disorders in Patients with Multiple Sclerosis—A Single-Center Study in the Polish Population, Medicina, 60, 3, (376), (2024).https://doi.org/10.3390/medicina60030376
    Crossref
  2. Neuroimaging and neuromodulation of invisible symptoms in multiple sclerosis, Frontiers in Human Neuroscience, 18, (2024).https://doi.org/10.3389/fnhum.2024.1376095
    Crossref
  3. Multiple sclerosis and personality traits: associations with depression and anxiety, European Journal of Medical Research, 29, 1, (2024).https://doi.org/10.1186/s40001-024-01772-0
    Crossref
  4. Depression and anxiety in MS: symptoms or comorbidity?, Multiple Sclerosis and Related Disorders, 88, (105758), (2024).https://doi.org/10.1016/j.msard.2024.105758
    Crossref
  5. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis, Multiple Sclerosis and Related Disorders, 81, (105139), (2024).https://doi.org/10.1016/j.msard.2023.105139
    Crossref
  6. Quantifying the Relationship Between Multiple Sclerosis Lesions and Depression, Biological Psychiatry, 95, 12, (1058-1059), (2024).https://doi.org/10.1016/j.biopsych.2024.04.008
    Crossref
  7. Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis, Biological Psychiatry, 95, 12, (1072-1080), (2024).https://doi.org/10.1016/j.biopsych.2023.11.010
    Crossref
  8. Neuropsychiatric Manifestations in Multiple Sclerosis and Other Demyelinating Diseases, Neuropsychiatric Manifestations in Neurological Diseases, (175-185), (2024).https://doi.org/10.1007/978-981-97-1821-4_18
    Crossref
  9. Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron, Brain Sciences, 13, 7, (1073), (2023).https://doi.org/10.3390/brainsci13071073
    Crossref
  10. A review on multiple sclerosis prognostic findings from imaging, inflammation, and mental health studies, Frontiers in Human Neuroscience, 17, (2023).https://doi.org/10.3389/fnhum.2023.1151531
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share